Skip to main content
OpenTrials
Completed

NCT Number: NCT04808609

Smoking Cessation Pilot for People Living With HIV (PLWH)

The overall goal of this pilot study is to evaluate the feasibility of the Lumme smartphone app for smoking cessation in people living with HIV (PLWH) and evaluate its effect on smoking cessation. Mobile health (mHealth) technology can be used for achieving health equity in vulnerable groups because it is a widely available and relatively inexpensive tool for health behavior change and can be adapted to meet the needs of its end-users. Therefore, a mHealth intervention such as the Lumme App proposed through this study is timely, relevant, scalable and likely to improve health outcomes in PLWH who smoke.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Cessation Acquired Immunodeficiency Syndrome Behavior Blood-Borne Infections Cigarette Smoking Communicable Diseases Genital Diseases HIV HIV Infections HIV/AIDS Health Behavior Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Smoking Smoking Behaviors Smoking Reduction Smoking, Cigarette Smoking, Tobacco Tobacco Smoking Tobacco Use Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Columbia University Irving Medical Center

New York, 10032, United States

About this study

Of the approximately one million persons living with HIV (PLWH) in the United States (U.S.), it is estimated that between 34-47% smoke cigarettes, around three times the prevalence (12.5%) observed in the general U.S. adult population. Consequently, PLWH experience substantial tobacco-related morbidity and mortality. In PLWH, after achieving and maintaining a suppressed viral load, smoking cessation is the next most important health behavior to maximize both quality of life and life expectancy. Given the high prevalence of cigarette smoking among PLWH and the benefit of smoking cessation, there is an urgent need for swift action to intervene to reduce tobacco use rates. However, evidence to improve tobacco cessation among PLWH is inadequate. Given the need for improving smoking cessation in PLWH, and the great promise of mHealth tools, this research study will assess smoking behaviors in people living with HIV and the subsequent efficacy of mHealth intervention for improving tobacco cessation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PLWH
  • ≥ 18 years old
  • own an Android smartphone
  • understand and read English
  • not pregnant or breastfeeding
  • permanent contact information
  • smokes greater than or equal to 5 cigarettes per day for the past 30 days
  • interested in quitting smoking within 30 days
  • blow ≥ 6 carbon monoxide (CO) into a breath analyzer at baseline

Exclusion criteria

  • self-report being HIV-negative or unknown status
  • pregnant, breastfeeding, or planning to become pregnant during the study period
  • planning to move within 3 months of enrollment
  • a positive history of a medical condition that precludes use of the nicotine patch
  • current use of nicotine replacement therapy or other smoking cessation medications
  • current enrollment in another smoking cessation program
  • blows ≤ 5 CO into a breath analyzer at baseline.

Treatment and study plan

Lumme mobile phone application

Device

Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors

Standard of Care

Behavioral

Smoking cessation counseling and nicotine replacement therapy

Primary outcomes

  1. Percentage of Participants With Biochemically Verified 7-day Point Prevalence Smoking/Tobacco Abstinence

    Time frame: Baseline, 12 weeks follow up

    7-day point prevalence abstinence was calculated as the percentage of participants who reported no smoking/tobacco use in the 7 days prior to their 12-week follow-up visit biochemically verified by exhaled Carbon Monoxide (eCO) collected at 12 weeks. Participants with eCO levels <6 parts per million (ppm) at 12 weeks were classified as abstinent while participants with eCO levels ≥6ppm at 12 weeks were classified as not abstinent.

Secondary outcomes

  1. Percentage of Participants With Self-reported 7-day Point Prevalence Abstinence at 12 Weeks

    Time frame: Baseline, 12 weeks follow up

    7-day point prevalence abstinence was calculated as the percentage of participants who reported no smoking/tobacco use in the 7 days prior to their 12-week follow-up visit.

  2. Change in eCO in Ppm From Baseline to 12-week Follow-up

    Time frame: Baseline to 12-week Follow-up

    Exhaled Carbon Monoxide (eCO) was measured via Micro +TM basic Smokerlyzer® in parts per million (ppm) and collected at Baseline and at 12-week Follow-up. Theoretically possible result values range from 0 to 150 ppm with higher values indicating more eCO. Mean change for this study was calculated as Baseline eCO value minus 12-week Follow-up eCO value such that positive mean values indicate a decrease in eCO from Baseline to 12-week Follow-up.

  3. Change in Center for Epidemiologic Studies Depression Scale (CES-D) Score

    Time frame: Baseline, 12-week Follow-up

    The CES-D measure contains 20 items asking respondents to rate how often over the past week they experienced depression-associated symptoms. Response options are coded as: 0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time. Scores are calculated by reversing scores for positive statements and adding all responses together. Scores range from 0 to 60, with higher scores indicating greater presence of depressive symptoms.

  4. Self-reported Number of Cigarettes Smoked Daily at Baseline

    Time frame: Baseline

    During baseline visit, participants were asked to report how many cigarettes they smoked daily during the past 30 days.

  5. CAGE Substance Abuse Screening Tool Score at Baseline

    Time frame: Baseline

    The CAGE Substance Abuse Screening Tool contains 4 questions with binary answer options: 1 = Yes, 0 = No. Scores are calculated by adding response values. Scores range from 0 to 4 with higher scores indicating alcohol problems. CAGE stands for the 4 question names: Cut down, Annoyed, Guilty, and Eye-opener

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Registry information

Official study title

A Pilot Trial of a Smoking Cessation App in People Living With HIV (PLWH)

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 22, 2021
Registry last updated
Feb 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.